自然感染的重症 COVID-19 患者对 SARS-CoV-2 变异株的交叉免疫。

Cross-immunity against SARS-COV-2 variants of concern in naturally infected critically ill COVID-19 patients.

作者信息

Fraser Douglas D, Patel Maitray A, Van Nynatten Logan R, Martin Claudio, Seney Shannon L, Miller Michael R, Daley Mark, Slessarev Marat, Cepinskas Gediminas, Juneja Ganeem K, Sabourin Vanessa, Fox-Robichaud Alison, Yeh Calvin H, Kim Paul Y, Badrnya Sigrun, Oehler Susanne, Miholits Markus, Webb Brian

机构信息

Lawson Health Research Institute, London, ON, N6C 2R5, Canada.

Pediatrics, Western University, London, ON, N6A 3K7, Canada.

出版信息

Heliyon. 2023 Jan;9(1):e12704. doi: 10.1016/j.heliyon.2022.e12704. Epub 2022 Dec 29.

DOI:10.1016/j.heliyon.2022.e12704

PMID:36594041

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9797417/

Abstract

Critically ill patients infected with SARS-CoV-2 display adaptive immunity, but it is unknown if they develop cross-reactivity to variants of concern (VOCs). We profiled cross-immunity against SARS-CoV-2 VOCs in naturally infected, non-vaccinated, critically ill COVID-19 patients. Wave-1 patients (wild-type infection) were similar in demographics to Wave-3 patients (wild-type/alpha infection), but Wave-3 patients had higher illness severity. Wave-1 patients developed increasing neutralizing antibodies to all variants, as did patients during Wave-3. Wave-3 patients, when compared to Wave-1, developed more robust antibody responses, particularly for wild-type, alpha, beta and delta variants. Within Wave-3, neutralizing antibodies were significantly less to beta and gamma VOCs, as compared to wild-type, alpha and delta. Patients previously diagnosed with cancer or chronic obstructive pulmonary disease had significantly fewer neutralizing antibodies. Naturally infected ICU patients developed adaptive responses to all VOCs, with greater responses in those patients more likely to be infected with the alpha variant, versus wild-type.

摘要

感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的危重症患者表现出适应性免疫，但他们是否对关注的变异株（VOCs）产生交叉反应尚不清楚。我们分析了自然感染、未接种疫苗的危重症冠状病毒病（COVID-19）患者对SARS-CoV-2 VOCs的交叉免疫情况。第1波患者（野生型感染）在人口统计学特征上与第3波患者（野生型/α感染）相似，但第3波患者的病情更严重。第1波患者对所有变异株产生的中和抗体不断增加，第3波患者也是如此。与第1波相比，第3波患者产生的抗体反应更强，尤其是对野生型、α、β和δ变异株。在第3波中，与野生型、α和δ相比，对β和γ VOCs的中和抗体明显较少。先前被诊断患有癌症或慢性阻塞性肺疾病的患者中和抗体明显较少。自然感染的重症监护病房患者对所有VOCs都产生了适应性反应，与野生型相比，那些更有可能感染α变异株的患者反应更强。